

**Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as
a highly protective, non-infectious vaccine against Ebola virus challenge**

Nicholas J. Lennemann^{1, #}, Andrew S. Herbert², Rachel Brouillette¹, Bethany Rhein¹, Russell A.
Bakken², Katherine J. Perschbacher¹, Ashley L. Cooney¹, Catherine M. Hunt^{1\$}, John M. Dye²,
and Wendy Maury^{1,*}

¹Department of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa,
USA. ²U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Fredrick,
Maryland, USA

[#]Present address: Department of Microbiology and Molecular Genetics, University of Pittsburgh
School of Medicine, Pittsburgh, PA, 15219, USA

^{\$}Present address: Dept. Biology, Western Illinois University, Macomb, IL, USA

*Corresponding author:

3-750 Bowen Science Building

51 Newton Road

Iowa City, IA 52242 USA

1 319 335 8021

wendy-maury@uiowa.edu

Running title: Pseudovirion vaccine against Ebola virus

21 **Abstract**

22 An epidemic caused by Ebola virus (EBOV) continues in West Africa, demonstrating the
23 significant public health burden of filovirus infections and highlighting the need for preventive
24 measures to combat the associated disease. Since, no vaccines or antivirals are currently FDA
25 approved, we sought to assess protection conferred by an EBOV vaccine composed of non-
26 infectious vesicular stomatitis virus (VSV) pseudovirions bearing EBOV glycoprotein (GP). A
27 prime/boost vaccination regime protected mice against lethal challenge with mouse-adapted
28 Ebola virus (MA-EBOV) in a dose-dependent manner. As N-linked glycans are thought to shield
29 conserved regions of GP, we also tested if pseudovirions containing GPs lacking N-linked
30 glycans on GP1 would provide effective immunity. High doses of GP/VSV partially or fully
31 denuded of N-linked glycans on GP1 protected mice against MA-EBOV challenge. However,
32 deglycosylated mutants proved less effective than WT GP/VSV at lower doses. Further, neither
33 N-linked glycan deficient GP/VSV provided significant cross protection against Sudan virus. As
34 others have reported, serum from vaccinated mice that were protected against lethal challenge
35 had few to no detectable neutralizing antibodies, indicating that EBOV vaccines do not need to
36 elicit neutralizing antibodies to protect against lethal challenge. A strong correlation was found
37 between the amount of vaccine-induced GP-specific Ig and protection. Our results show that
38 non-infectious GP/VSV pseudovirions serve as a successful vaccination platform, but reduction
39 of the glycan shield is not an effective means of enhancing immunogenicity of EBOV GP.
40 Further, we identify that GP-specific Ig levels provide a good immune correlate of protection.

41

42 **Importance**

43 The current West Africa Ebola virus epidemic continues despite international efforts. While
44 human vaccine trials are underway, no FDA-approved vaccines are yet available and it remains
45 unclear which vaccine platform will serve as the most efficacious and safest approach. Here, we
46 test the efficacy of a novel filovirus vaccine platform and find that wild-type Ebola virus
47 glycoprotein, in the context of this platform, provides robust protection. Further, we investigated
48 if removal of the heavy glycan shield surrounding the glycoprotein enhances vaccine efficacy.
49 Surprisingly, we found that removal of glycans decreases the efficacy of the vaccine, reducing
50 the protection offered against lethal challenge with Ebola virus.

51 **Introduction**

52 Filoviruses, such as Ebola virus (EBOV) and Marburg virus (MARV), cause sporadic
53 outbreaks of viral hemorrhagic fever throughout Central Africa. At the time of this report, a
54 EBOV epidemic continues in West Africa, a region that has not previously experienced filovirus
55 outbreaks (13).

56 A number of different vaccine platforms that express the filovirus glycoprotein (GP) have
57 proven to be effective at protecting against lethal homotypic filovirus challenge in animal models
58 (15, 31-35, 38, 40). This series of studies has led the field to conclude that immune responses
59 against filovirus GPs are necessary and sufficient for protection. Vaccine platforms expressing
60 the filoviral GP that have proved efficacious in at least one animal model include: DNA
61 plasmids, adenoviral vectors, virus-like particles, recombinant Venezuelan equine encephalitis
62 virus particles and infectious recombinant viruses, such as human parainfluenza virus type 3,
63 rabies virus and vesicular stomatitis virus (VSV) (reviewed in (7, 11)). Surprisingly, EBOV GP
64 pseudovirions have not been assessed for their efficacy as a vaccine platform. EBOV GP
65 pseudotyped on to vesicular stomatitis virus (VSV) has many advantages as a vaccine platform,
66 including ease of production and characterization, absence of virus replication concerns and the
67 robust immune stimulatory activity associated with VSV proteins (5).

68 The highly effective EBOV immunogen, GP, is produced from a pro-protein that is
69 processed by furin in cells to produce GP1/GP2 heterodimers. These class I heterodimeric
70 glycoproteins reside as trimers on the surface of infected cells and virions. Mature GP1 sits on
71 top GP2 which is anchored in the membrane. GP1 contains four different domains, including a
72 base, receptor-binding domain (RBD), glycan cap and mucin-like domain (MLD). The first three
73 domains compose the core of GP1 and are required for expression and function of the pre-fusion

glycoprotein, whereas the MLD is not required for virion entry or GP expression (14). GP1 is extensively glycosylated with approximately half of the mature GP mass contributed by N- and O-linked glycans (14). Fifteen N-linked glycans are found on EBOV GP1 and as many as 80 O-linked glycans are thought to be present on the MLD (14, 21, 22). The transmembrane protein GP2 contains two N-linked glycans on its ectodomain that are conserved throughout the entire virus family (14, 21, 23).

Glycans on viral glycoproteins have been shown to facilitate immune evasion through shielding the protein from neutralizing antibodies (1, 2, 8, 19, 39, 41). For example, antibodies raised against influenza A virus hemagglutinin (HA), bearing truncated glycans, have enhanced antigen binding and neutralization of virus. Furthermore, decreasing the complexity of N-linked glycans on HA increased the efficacy of a HA subunit vaccine in mice (39). Previous work with EBOV indicated that vaccination with virus-like particles (VLPs) expressing EBOV GP lacking the MLD resulted in up to 2.5-fold higher neutralizing antibody titers compared to wild-type (WT) GP on VLPs (25), suggesting glycan shielding compromises EBOV GP immunogenicity. Occlusion of the GP1 RBD is thought to be conferred by N-linked glycans present on the core of GP1 and N- and O-linked glycans on the MLD as shown in Figure 1A (left panel). Consistent with the possibility that glycan shielding might reduce immune responses to EBOV GP, we have previously shown that removal of all N-linked glycans from EBOV GP1 increases convalescent antibody-dependent neutralization without compromising GP incorporation into VSV pseudovirions (22). By modeling, complete elimination of N-linked glycans on GP1 as is found on our GP mutant 7Gm8G would be predicted to result in greater surface availability of the highly conserved GP1 RBD (Figure 1A, right panel). In contrast to these studies, a previous study by Dowling, et al. hinted that loss of glycans might decrease the immune-stimulating

97 efficiency of EBOV GP. They demonstrated that protection offered by GP was diminished by
98 deleting the MLD or mutation of one of the two GP2 N-glycans (6).

99 Here, we evaluate the efficacy of EBOV GP pseudotyped onto VSV as a vaccine
100 candidate and find robust protection conferred against lethal challenge with mouse-adapted
101 EBOV (MA-EBOV). Protection strongly associated with production of EBOV GP-specific
102 immunoglobulins. We also assessed if removal of N-linked glycans from EBOV GP1 leads to
103 increased immunogenicity and improved vaccine efficacy by exposing epitopes that are masked
104 in the RBD of the WT GP. Further, we evaluated if these deglycosylated GPs provide better
105 cross protection against other *Ebolavirus* members, such as Sudan virus (SUDV). We
106 demonstrate that these N-linked glycan site (NGS) mutants provide poorer protection against
107 MA-EBOV challenge and offer little to no protection against SUDV challenge.

109 **Materials and Methods**

110 **Cell lines and plasmids.** Vero cells and HEK293T cells were maintained in Dulbecco's
111 Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 1%
112 penicillin/streptomycin. The pcDNA3.1 expression plasmids for EBOV GP (accession number:
113 NP_066246) and the N-linked glycan-deficient GP1 mutants 7G and 7Gm8G have been
114 previously described (22). Codon optimized SUDV-Boniface GP (a gift from Robert Davey,
115 accession number: Q66814) containing a Q95K mutation, which we have determined increases
116 pseudovirion titer (data not shown), was expressed from pcDNA3.1. The pCAGGS vector was
117 used to express codon optimized Lassa virus - Josiah (LASV) glycoprotein (accession number:
118 NP_694870).

Modeling of GP N-linked glycans. The addition of complex N-linked glycans to the pre-fusion EBOV GP_{1,2} ΔTM structure (PDB ID: 3CSY) that lacks the MLD was performed as previously described (22, 23). Briefly, the published structure lacks four NGS in GP1 due to disordered regions missing from the structure (N204 and N296) or mutations that promoted crystallization (N40 and N228) (20, 21). The EBOV GP sequence was submitted to the PHYRE2 protein fold recognition server (16), which provided a structure that contained NGS at N40 and N228. This structure was submitted for *in silico* glycosylation using the GlyProt server (glycosciences.de), which produced a model containing complex N-linked glycans at all NGS, except N204 and N296, which are part of disordered regions (21). Complex glycans at these sites were modeled onto the glycosylated structure at predicted sites with PyMol.

Production of VSV/GFP pseudovirions. Pseudovirions were produced in HEK293T cells as previously described (17, 37). Briefly, HEK293T cells were transfected with the various viral GP-expressing constructs and at 24 h transduced by an infection defective vesicular stomatitis virus that lacks the gene encoding the native G glycoprotein (VSVΔG-GFP) pseudotyped with LASV GPC. In the genome of VSVΔG-GFP, glycoprotein G gene is replaced with the green fluorescence protein gene (GFP). After 24 h, cell supernatants were collected and filtered through 0.45 μm syringe-filters followed by storage at -80°C. Pseudovirions were concentrated overnight by centrifugation at 5400 x g. Virus was resuspended in PBS and pelleted through a 20% sucrose cushion for 2 h at 83,000 x g and resuspended in PBS, treated with Detoxi-Gel endotoxin removing resin (Thermo Scientific) to remove any endotoxin in our preparations. All virus stocks were frozen at -80°C until use.

VSV-matrix quantification to normalize pseudovirion administration. Assessment of VSV-matrix (M) in pseudovirion preparations was performed as previously described (22). Briefly,

pseudovirion stocks were passed through a dot blot apparatus onto nitrocellulose. VSV-M was detected with mouse anti-VSV-M mAb 23H12 (24). Signals were quantified using the Odyssey Imaging Station and Image Studio software (LI-COR).

Transduction assays. Vero cells were seeded in 48-well plates 24 h prior to transduction. Serial dilutions of WT EBOV GP/VSV pseudovirion stocks were added to Vero cell monolayers. Transduction was determined by quantification of GFP expressing cells by flow cytometry 24 h following addition of pseudovirions.

Ethics statement. Animal research at the University of Iowa was conducted under a protocol approved by the University of Iowa Institutional Animal Care and Use Committee (IACUC) in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals. Animal research was conducted under a protocol approved by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Institutional Animal Care and Use Committee (IACUC) in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals. Both facilities are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International and adhere to the principles stated in the *Guide for the Care and Use of Laboratory Animals* (National Research Council, 2011).

Challenge studies were conducted under maximum containment in the USAMRIID animal biosafety level 4 (ABSL-4) facility.

Vaccinations and EBOV challenges. The amount of the different pseudovirions administered in each vaccine study was based on equivalent matrix levels to that of EBOV GP/VSV. In all challenge studies using mouse-adapted EBOV, mice were challenged with greater than 3000

lethal dose₅₀ (LD₅₀) of mouse-adapted Ebola virus (MA-EBOV) intraperitoneally (i.p.).

Depending on the stock used, a dose of 3000 LD₅₀ ranged from 100 to 1000 pfu.

Experiment 1: 4-8 week old BALB/c males and females (n=9/group) were administered 2×10^7 WT EBOV GP/VSV transducing units (TU) in PBS intramuscularly (i.m.) as a prime and then a boost 3 weeks later. The quantity of SUDV GP/VSV pseudovirions administered was based on matrix equivalents to that of EBOV GP/VSV using the same prime/boost strategy. Vaccinated mice were shipped to USAMRIID (Fort Detrick, MD) where at 7 weeks after initiation of the vaccination regime they were challenged with greater than 3000 lethal dose₅₀ (LD₅₀) of mouse-adapted Ebola virus (MA-EBOV) intraperitoneally (i.p.).

Experiment 2: 6 week old C57bl/6 females were purchased from Charles River. Ten-fold serial dilutions in PBS of WT EBOV GP/VSV pseudovirions (2×10^2 to 2×10^7 TU) were given i.m. as a prime and then a boost 3 weeks later (n=10/group). The quantity of other VSV pseudovirions (7G and 7Gm8G) administered was based on matrix equivalents to that of EBOV GP/VSV using the same dilution series and prime/boost strategy. Vaccinated mice were shipped to USAMRIID (Fort Detrick, MD) where at seven weeks following initiation of the vaccination regime, mice were challenged with greater than 3000 lethal dose₅₀ (LD₅₀) of mouse-adapted Ebola virus (MA-EBOV) intraperitoneally (i.p.). Challenged mice were observed daily for lethality or clinical signs of disease, including, but not limited to, reduced grooming, hypo-activity and weight loss. Daily observations were increased to a minimum of twice daily while mice were exhibiting signs of disease. Moribund mice were humanely euthanized based on IACUC-approved criteria

Experiment 3: 4- 8 week old male and female mice lacking the interferon alpha/beta receptor (C57bl/6.129S2-Ifnar1tm1Agt/Mmjax; referred to in this publication as IFNAR^{-/-}) were purchased from Jackson Laboratories (Bar Harbor, ME) and used for all SUDV challenge

experiments (n= 10/group). Upon arrival, mice were housed in microisolater cages and provided chow and water *ad libitum*. All vaccinated mice received the matrix equivalents of 2×10^7 transducing units of WT EBOV GP/VSV i.m. in a prime/boost regime. Seven weeks following vaccinations, mice were challenged i.p. with 1000 pfu of SUDV (Boniface isolate) or 1000 pfu of WT EBOV. Mice were monitored daily as described above.

IgG titers and neutralization assays. Serum was taken from mice in our second vaccination study (serial dilution study) and assessed for immunoglobulin detecting the core of WT EBOV GP by ELISA. Briefly, 2×10^5 TU of purified EBOV GPΔMLD/FIV pseudovirions (as assessed on SNB-19 cells) were coated overnight in PBS at 4°C in an Immulon HB 96-well plate. FIV pseudovirions were generated as previously described (12). Virus was diluted in PBS. The standard curve was composed of a two-fold dilution series of mouse Ig fraction (ImmunoReagent, Inc). Plates were blocked for 1h at room temperature with PBS with 2% bovine serum albumin (BSA), incubated with serial dilutions (1:1000, 1:10,000 and 1:1000,000) of serum for overnight at 4°C, probed with 1 µg/ml HRP-conjugated rabbit anti-mouse (Pierce) for 1 h and wells were assessed for HRP activity with UltraTMB (Thermo). Absorbance was read at 405 nm.

To assess the ability of our vaccinated mouse serum to neutralize EBOV GP transduction, serial dilutions of serum were incubated with WT EBOV GP VSV pseudovirions (WT MOI ~0.3), for 30 min at 37 °C. Reactions were then diluted 5-fold in media and used to transduce confluent monolayers of Vero cells. Inhibition curves and half maximal inhibitory concentrations (IC₅₀) were determined using GraphPad Prism 5.

Results

Vaccination regimen and challenge timing are shown in Figure 1B. In initial studies, we determined if EBOV GP/VSV pseudovirions protect against MA-EBOV challenge. Mice were primed i.m. with 2×10^7 TU of VSV lacking the native G glycoprotein gene and pseudotyped with EBOV GP or SUDV GP. Three weeks later, the same quantity of viruses was re-administered to the mice as a boost. A PBS injection served as the control. Mice were challenged i.p. with 1000 PFU of mouse-adapted Ebola virus (MA-EBOV) approximately 7 weeks after the prime. Challenged mice were monitored for 28 days post infection (dpi) (Figure 1C). While none of the PBS group survived, 8 out of 9 EBOV GP/VSV vaccinated mice were protected from challenge. In contrast, SUDV GP/VSV-vaccinated mice were poorly protected against MA-EBOV challenge. Consistent with the survival findings, GP/VSV vaccinated mice trended towards lower average sickness scores than the PBS controls or the SUDV/VSV-vaccinated mice (Figure 1D). The poor cross protection provided by SUDV GP/VSV against MA-EBOV challenge was not unexpected as the lack of sufficient cross protection against other *Ebolavirus* species has been previously reported (15, 26). These studies provided an initial indication that our VSV pseudovirions bearing EBOV GP offers effective protection against homotypic challenge.

In a second study, we assessed the efficacy of our vaccine platform over a range of concentrations of viral particles containing WT EBOV GP. Additionally, we evaluated if our partially or fully deglycosylated pseudovirions conferred similar protection to that provided by our WT virions. In this study, 6 week old C57bl/6 females were given a prime/boost regimen of 2×10^2 to 2×10^7 TU of EBOV GP/VSV, 7G/VSV or 7Gm8G/VSV. Vaccinated mice were challenged with 100 pfu of MA-EBOV at seven weeks following the initial prime and monitored

for 28 dpi. As expected, mice given PBS succumbed to disease 6-7 dpi (Figure 2). The two highest doses of all three EBOV GP pseudovirion vaccines protected against lethal MA-EBOV challenge (Figure 2A and B).

Lower doses of VSV pseudovirions bearing 7G, or 7Gm8G proved to be less effective than EBOV GP/VSV. The reduced efficacy of our deglycosylated GP pseudovirions became evident at prime/boosts composed of 2×10^5 TU or less (Figure 2C-F), indicating that mutation of NGS within GP1 decreased the immunogenicity of GP rather than improving it.

To determine if exposure of highly conserved regions of GP1 through deglycosylation led to quantitative changes in anti-EBOV GP antibodies, we assessed the amount of immunoglobulin (Ig) in convalescent serum from each vaccination group that bound to EBOV GPΔMLD pseudotyped on to feline immunodeficiency virus (Figure 3A). A MLD-deleted EBOV GP was selected as the target in these ELISAs since recent findings indicate that antibodies against the core of EBOV GP are sufficient for protection (29). The quantity of anti-EBOV GP Ig produced by the different vaccination treatments correlated strongly with dose of immunogen administered (Figure 3A and B). High levels of Ig were detected with doses of either 2×10^6 or 2×10^7 TU, independent of the glycosylation status of the GP. However, with administration of intermediate concentrations of pseudovirions, more anti-EBOV GP antibodies were detected in the EBOV GP pseudovirions group than either partially deglycosylated (7G) or fully deglycosylated (7Gm8G) as evidenced by the trend line (Figure 3B). A strong, positive correlation between the amount of anti-EBOV GP Ig and the percentage of survival for each group was also evident (Figure 3C), suggesting that anti-EBOV GP Ig production might serve as a good immune correlate for vaccine protection.

Given the positive association of serum neutralizing antibodies with survival against EBOV in human and animal model infections (18, 36, 40) and our observed correlation between survival and anti-EBOV GP antibody levels in convalescent serum, we evaluated convalescent sera from vaccinated mice for the ability to neutralize transduction by EBOV GP/VSV pseudovirions. Sera from mice vaccinated with either 2×10^7 or 2×10^6 TU of WT EBOV GP/VSV contained modest levels of neutralizing antibodies (Figure 3D). Neither GP mutant elicited detectable neutralizing antibody responses even at the highest concentrations of immunogen, despite providing robust protection against lethal challenge. These results indicate that VSV pseudovirion-based vaccines against EBOV elicit a protective immune response independent of neutralizing antibodies. Interestingly, protection conferred by other EBOV vaccines is not always reported to be strongly correlated with the production of high levels of neutralizing antibodies (26, 30).

Finally, we evaluated the possibility that our EBOV GP immunogens lacking N-linked glycans could provide cross protection against the distantly related ebolavirus, SUDV-Boniface. A similar vaccination schedule was used in this study, injecting a prime/boost of 2×10^7 7G or 7Gm8G pseudovirions into C57bl/6 mice lacking the interferon α/β receptor (IFNAR^{-/-}). IFNAR^{-/-} mice were used in these experiments as a mouse-adapted strain of SUDV that is lethal to immunocompetent mice is not currently available and previous work has demonstrated that IFNAR^{-/-} mice have significant and consistent weight loss upon WT SUDV infection (10). WT EBOV GP pseudovirions were not evaluated for their ability to confer protection against SUDV as others have previously demonstrated that WT EBOV GP does not provide cross protection (10). Mice vaccinated with PBS, SUDV GP/VSV, 7G GP/VSV or 7Gm8G/VSV pseudovirions were challenged with 1000 PFU of WT SUDV(Boniface) i.p. and mice were weighed daily as

previously described (3, 4). While SUDV GP/VSV pseudovirions protected against weight loss, 7G nor 7Gm8G had weight loss similar to that of pseudovirions bearing Lassa virus GPC or the PBS control, indicating our deglycosylated mutant EBOV GPs were unable to provide protection, despite that the same vaccination dosage protected well against WT EBOV challenge (Figure 4A and B).

Discussion

In the present study, we sought to determine if a prime/boost vaccination of mice with non-infectious VSV pseudotyped with EBOV GP provides protection from lethal EBOV challenge. We found that prime/boost administration of 2×10^5 TU or greater of EBOV GP/VSV proved efficacious. Protection was observed in both BALB/c and C57bl/6 mice, indicating that the vaccine was effective independent of the strain of mouse used. These findings provide evidence that VSV pseudovirion-based vaccines may provide a highly effective and safe alternative to the infectious recombinant VSV platform that is currently in human trials.

Through our dose response studies, we have identified that total anti-EBOV GP Ig levels serve as an excellent immune marker predictive for protection. Not surprisingly, the amount of EBOV GP-specific Ig that was detected was strongly correlated with the dosage of pseudovirions administered. Regardless of the glycosylation status of the virions, doses of 2×10^6 TU or higher resulted in anti-EBOV GP Ig levels of 135 μ g/ml or higher in our assay and protected 90 to 100% of mice from lethal MA-EBOV challenge. Vaccine doses that resulted in production of 30 to 60 μ g/ml of EBOV GP-specific Ig provided 30 to 60% protection and doses producing Ig levels similar to that of the PBS control provided no significant protection. Interestingly, this robust correlation with Ig responses was not associated with detectable neutralization of EBOV

GP/VSV pseudovirions in our in vitro assays. In combination, our findings suggest that our vaccine elicits protective humoral responses that do not involve neutralization of viral particle in in vitro assays.

We also explored if increased protection was conferred by pseudovirions containing EBOV GP to pseudovirions containing mutant EBOV GPs lacking N-linked glycans on GP1. Interestingly, decreasing the glycan shield on EBOV GP diminished the ability of moderate vaccine doses to protect against MA-EBOV, indicating that loss of EBOV GP1 NGS is not an effective strategy to increase immunogenicity of EBOV GP. As we have shown that elimination of GP1 NGS increases the sensitivity of GP to endosomal proteolytic processing (22), it is possible that removal of N-linked glycans decreases the stability and antigen presentation of GP *in vivo*, resulting in poor immune stimulation at lower doses.

These studies also demonstrate that pseudovirions bearing NGS-denuded GP1 provide poor cross protection against SUDV challenge. Thus, our studies provide no evidence that an EBOV GP immunogen lacking NGS on GP1 elicits novel protective immune responses to highly conserved regions of GP. To date, the most effective cross-protection has been achieved through combinatorial vaccines that present proteins from multiple viral species to the host (9, 10, 26-28, 31). Together with our results, a mixture of VSV pseudotyped with representative GPs from the filovirus family could provide an efficient and safe vaccine that warrants further investigation in other animal model systems.

Acknowledgements

Opinions, conclusions, interpretations, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army. The mention of trade names or commercial products does not constitute endorsement or recommendation for use by the Department of the Army or the Department of Defense. This work was supported by funding from the National Institutes of Health (R01 AI077519 to WM, T32AI007533 to support NL, T32 AI996343 to support CMH) and Department of Defense (CB3947 to JD).

References

1. **Aguilar, H. C., K. A. Matreyek, C. M. Filone, S. T. Hashimi, E. L. Levroney, O. A. Negrete, A. Bertolotti-Ciarlet, D. Y. Choi, I. McHardy, J. A. Fulcher, S. V. Su, M. C. Wolf, L. Kohatsu, L. G. Baum, and B. Lee.** 2006. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. *J Virol* **80**:4878-89.
2. **Biering, S. B., A. Huang, A. T. Vu, L. R. Robinson, B. Bradel-Tretheway, E. Choi, B. Lee, and H. C. Aguilar.** 2012. N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. *J Virol* **86**:11991-2002.
3. **Brannan, J. M., J. W. Froude, L. I. Prugar, R. R. Bakken, S. E. Zak, S. P. Daye, C. E. Wilhelmsen, and J. M. Dye.** 2015. Interferon alpha/beta Receptor-Deficient Mice as a Model for Ebola Virus Disease. *J Infect Dis*.
4. **Chen, G., J. F. Koellhoffer, S. E. Zak, J. C. Frei, N. Liu, H. Long, W. Ye, K. Nagar, G. Pan, K. Chandran, J. M. Dye, S. S. Sidhu, and J. R. Lai.** 2014. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. *ACS Chem Biol* **9**:2263-73.
5. **Cobleigh, M. A., C. Bradfield, Y. Liu, A. Mehta, and M. D. Robek.** 2012. The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. *J Virol* **86**:4253-61.
6. **Dowling, W., E. Thompson, C. Badger, J. L. Mellquist, A. R. Garrison, J. M. Smith, J. Paragas, R. J. Hogan, and C. Schmaljohn.** 2007. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. *J Virol* **81**:1821-37.
7. **Friedrich, B. M., J. C. Trefry, J. E. Biggins, L. E. Hensley, A. N. Honko, D. R. Smith, and G. G. Olinger.** 2012. Potential vaccines and post-exposure treatments for filovirus infections. *Viruses* **4**:1619-50.
8. **Helle, F., G. Vieyres, L. Elkrief, C. I. Popescu, C. Wychowski, V. Descamps, S. Castelain, P. Roingeard, G. Duverlie, and J. Dubuisson.** 2010. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. *J Virol* **84**:11905-15.

9. **Hensley, L. E., S. Mulangu, C. Asiedu, J. Johnson, A. N. Honko, D. Stanley, G. Fabozzi, S. T. Nichol, T. G. Ksiazek, P. E. Rollin, V. Wahl-Jensen, M. Bailey, P. B. Jahrling, M. Roederer, R. A. Koup, and N. J. Sullivan.** 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. *PLoS Pathog* **6**:e1000904.
10. **Herbert, A. S., A. I. Kuehne, J. F. Barth, R. A. Ortiz, D. K. Nichols, S. E. Zak, S. W. Stonier, M. A. Muhammad, R. R. Bakken, L. I. Prugar, G. G. Olinger, J. L. Groebner, J. S. Lee, W. D. Pratt, M. Custer, K. I. Kamrud, J. F. Smith, M. K. Hart, and J. M. Dye.** 2013. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. *J Virol* **87**:4952-64.
11. **Hoenen, T., A. Groseth, and H. Feldmann.** 2012. Current ebola vaccines. *Expert Opin Biol Ther* **12**:859-72.
12. **Hunt, C. L., A. A. Kolokoltsov, R. A. Davey, and W. Maury.** 2011. The tyro3 receptor kinase axl enhances macropinocytosis of zaire ebolavirus. *J Virol* **85**:334-47.
13. **Incident Management System Ebola Epidemiology Team, C. D. C., V. Guinea Interministerial Committee for Response Against the Ebola, O. World Health, C. D. C. G. R. Team, H. Liberia Ministry of, W. Social, C. D. C. L. R. Team, H. Sierra Leone Ministry of, Sanitation, C. D. C. S. L. R. Team, N. C. f. E. Viral Special Pathogens Branch, and C. D. C. Zoonotic Infectious Diseases.** 2015. Update: ebola virus disease epidemic - west Africa, january 2015. *MMWR Morb Mortal Wkly Rep* **64**:109-10.
14. **Jeffers, S. A., D. A. Sanders, and A. Sanchez.** 2002. Covalent modifications of the ebola virus glycoprotein. *J Virol* **76**:12463-72.
15. **Jones, S. M., H. Feldmann, U. Stroher, J. B. Geisbert, L. Fernando, A. Grolla, H. D. Klenk, N. J. Sullivan, V. E. Volchkov, E. A. Fritz, K. M. Daddario, L. E. Hensley, P. B. Jahrling, and T. W. Geisbert.** 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. *Nat Med* **11**:786-90.
16. **Kelley, L. A., and M. J. Sternberg.** 2009. Protein structure prediction on the Web: a case study using the Phyre server. *Nat Protoc* **4**:363-71.
17. **Kondratowicz, A. S., N. J. Lennemann, P. L. Sinn, R. A. Davey, C. L. Hunt, S. Moller-Tank, D. K. Meyerholz, P. Rennert, R. F. Mullins, M. Brindley, L. M. Sandersfeld, K. Quinn, M. Weller, P. B. McCray, Jr., J. Chiorini, and W. Maury.** 2011. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. *Proc Natl Acad Sci U S A* **108**:8426-31.
18. **Konduru, K., S. B. Bradfute, J. Jacques, M. Manangeeswaran, S. Nakamura, S. Morshed, S. C. Wood, S. Bavari, and G. G. Kaplan.** 2011. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. *Vaccine* **29**:2968-77.
19. **Kong, L., E. Giang, J. B. Robbins, R. L. Stanfield, D. R. Burton, I. A. Wilson, and M. Law.** 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. *Proc Natl Acad Sci U S A* **109**:9499-504.
20. **Lee, J. E., M. L. Fusco, D. M. Abelson, A. J. Hessel, D. R. Burton, and E. O. Saphire.** 2009. Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. *Acta Crystallogr D Biol Crystallogr* **65**:1162-80.

21. **Lee, J. E., M. L. Fusco, A. J. Hessel, W. B. Oswald, D. R. Burton, and E. O. Saphire.** 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. *Nature* **454**:177-82.
22. **Lennemann, N. J., B. A. Rhein, E. Ndungo, K. Chandran, X. Qiu, and W. Maury.** 2013. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. *MBio* **5**:e00862-13.
23. **Lennemann, N. J., M. Walkner, A. R. Berkebile, N. Patel, and W. Maury.** 2015. The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2. *J Infect Dis.*
24. **Lyles, D. S., L. Puddington, and B. J. McCreedy, Jr.** 1988. Vesicular stomatitis virus M protein in the nuclei of infected cells. *J Virol* **62**:4387-92.
25. **Martinez, O., L. Tantral, N. Mulherkar, K. Chandran, and C. F. Basler.** 2011. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. *J Infect Dis* **204 Suppl 3**:S825-32.
26. **Marzi, A., H. Ebihara, J. Callison, A. Groseth, K. J. Williams, T. W. Geisbert, and H. Feldmann.** 2011. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. *J Infect Dis* **204 Suppl 3**:S1066-74.
27. **Mire, C. E., J. B. Geisbert, A. Marzi, K. N. Agans, H. Feldmann, and T. W. Geisbert.** 2013. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. *PLoS Negl Trop Dis* **7**:e2600.
28. **Mire, C. E., J. B. Geisbert, K. M. Versteeg, N. Mamaeva, K. N. Agans, T. W. Geisbert, and J. H. Connor.** 2015. A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs. *J Infect Dis.*
29. **Murin, C. D., M. L. Fusco, Z. A. Bornholdt, X. Qiu, G. G. Olinger, L. Zeitlin, G. P. Kobinger, A. B. Ward, and E. O. Saphire.** 2014. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. *Proc Natl Acad Sci U S A* **111**:17182-7.
30. **Phoolcharoen, W., J. M. Dye, J. Kilbourne, K. Piensook, W. D. Pratt, C. J. Arntzen, Q. Chen, H. S. Mason, and M. M. Herbst-Kralovetz.** 2011. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. *Proc Natl Acad Sci U S A* **108**:20695-700.
31. **Pratt, W. D., D. Wang, D. K. Nichols, M. Luo, J. Woraratanadharm, J. M. Dye, D. H. Holman, and J. Y. Dong.** 2010. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. *Clin Vaccine Immunol* **17**:572-81.
32. **Pushko, P., M. Bray, G. V. Ludwig, M. Parker, A. Schmaljohn, A. Sanchez, P. B. Jahrling, and J. F. Smith.** 2000. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. *Vaccine* **19**:142-53.
33. **Rao, M., M. Bray, C. R. Alving, P. Jahrling, and G. R. Matyas.** 2002. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. *J Virol* **76**:9176-85.
34. **Sullivan, N. J., T. W. Geisbert, J. B. Geisbert, L. Xu, Z. Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel.** 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. *Nature* **424**:681-4.

- 452 35. **Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel.** 2000.
453 Development of a preventive vaccine for Ebola virus infection in primates. *Nature*
454 **408**:605-9.
- 455 36. **Sun, Y., R. Carrion, Jr., L. Ye, Z. Wen, Y. T. Ro, K. Brasky, A. E. Ticer, E. E.**
456 **Schwegler, J. L. Patterson, R. W. Compans, and C. Yang.** 2009. Protection against
457 lethal challenge by Ebola virus-like particles produced in insect cells. *Virology* **383**:12-
458 21.
- 459 37. **Takada, A., C. Robison, H. Goto, A. Sanchez, K. G. Murti, M. A. Whitt, and Y.**
460 **Kawaoka.** 1997. A system for functional analysis of Ebola virus glycoprotein. *Proc Natl*
461 *Acad Sci U S A* **94**:14764-9.
- 462 38. **Vanderzanden, L., M. Bray, D. Fuller, T. Roberts, D. Custer, K. Spik, P. Jahrling, J.**
463 **Huggins, A. Schmaljohn, and C. Schmaljohn.** 1998. DNA vaccines expressing either
464 the GP or NP genes of Ebola virus protect mice from lethal challenge. *Virology* **246**:134-
465 44.
- 466 39. **Wang, C. C., J. R. Chen, Y. C. Tseng, C. H. Hsu, Y. F. Hung, S. W. Chen, C. M.**
467 **Chen, K. H. Khoo, T. J. Cheng, Y. S. Cheng, J. T. Jan, C. Y. Wu, C. Ma, and C. H.**
468 **Wong.** 2009. Glycans on influenza hemagglutinin affect receptor binding and immune
469 response. *Proc Natl Acad Sci U S A* **106**:18137-42.
- 470 40. **Warfield, K. L., C. M. Bosio, B. C. Welcher, E. M. Deal, M. Mohamadzadeh, A.**
471 **Schmaljohn, M. J. Aman, and S. Bavari.** 2003. Ebola virus-like particles protect from
472 lethal Ebola virus infection. *Proc Natl Acad Sci U S A* **100**:15889-94.
- 473 41. **Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-**
474 **Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B.**
475 **H. Hahn, P. D. Kwong, and G. M. Shaw.** 2003. Antibody neutralization and escape by
476 HIV-1. *Nature* **422**:307-12.
477

Figure legends

Figure 1: Vaccination/challenge regimen demonstrating protection against homotypic challenge.

(A) Top-down view of models of EBOV GP and a GP mutant fully deglycosylated for GP1 N-linked glycans. RBD is shown in red, glycan cap is shown in teal, GP2 is shown in tan, N-linked glycans are shown in orange, and the MLD (not included in the crystal structure) is modeled as a gray sphere. Two N-linked glycans found on GP2 were not mutated in our glycosylation mutants investigated in these studies and are shown around the base of GP2. *Left*, WT GP; *right*, 7Gm8G mutant lacking all GP1 N-linked glycans indicated by the absence of orange glycans modeled on GP1 and an increase in transparency of the MLD. (B) Vaccination regimen. (C) Protection conferred by 2×10^7 TU of EBOV GP/VSV pseudovirions ($n = 9/\text{group}$) upon challenge of BALB/c mice with 1000 PFU of MA-EBOV. Significance was determined by Mantel-Cox Test, $** p < 0.001$. (D) Sickness score of surviving mice at indicated days post infection. Data are presented as average $\pm$ SD.

Figure 2: Survival of C57bl/6 females vaccinated with the indicated transducing units (TU) of VSV lacking its native glycoprotein and pseudotyped with EBOV GP (black lines), 7G (green lines), or 7Gm8G (blue lines) ($n = 10/\text{treatment}$). Transducing units (TU) were determined by Vero cell transduction of VSV/EBOV GP; pseudovirion equivalent of mutant viruses were normalized to WT levels by the quantity of VSV matrix in each stock. Vaccinated mice were challenged with 100 pfu MA-EBOV and monitored for 28 days. For comparison, the PBS control is shown for each dosage. Survival of PBS control mice was compared to the other vaccine treatments with significance determined by Mantel-Cox Test, $*p < 0.01$, $**p < 0.001$.

Figure 3: Humoral responses in mice vaccinated with WT EBOV GP/VSV were more robust than that of mice vaccinated with deglycosylated pseudovirions. Sera were collected from vaccinated mice three weeks following boost. (A) Anti-EBOV GP Ig levels. Dashed line represents Ig levels observed in PBS-treated mice. (B) Correlation between the quantity of pseudovirus administered as a vaccine and Ig production. Trend line for each vaccine treatment is shown independently. (C) Correlation between group survival and anti-EBOV GP Ig in sera. Trend line is shown for pooled results from all three pseudovirion treatments. (D) Neutralizing activity present in vaccinated mice sera. Serum was serially diluted and incubated with EBOV GP/VSV for 30 minutes at 37°C prior to addition to Vero cells. Data are shown as transduction (GFP positive cells) presented as a percentage of PBS control. Significant differences in neutralization conferred by EBOV GP compared to either of the deglycosylated EBOV GP groups were determined by two-way ANOVA with Tukey post hoc analysis, * $p < 0.05$; ** $p < 0.005$; *** $p < 0.0001$.

Figure 4: VSV pseudovirions bearing deglycosylated EBOV GP do not provide protection against SUDV challenge. C57bl/6 IFNAR^{-/-} (n=10 mice) were primed and boosted with 2×10^7 TU of the indicated VSV pseudovirions followed by challenge with (A) 1000 pfu of WT SUDV or (B) 1000 pfu of WT EBOV. Percentage of weight loss is shown at the indicated time following infection.




Figure 1: Vaccination/challenge regimen demonstrating protection against homotypic challenge. (A) Top-down view of models of EBOV GP and a GP mutant fully deglycosylated for GP1 N-linked glycans. RBD is shown in red, glycan cap is shown in teal, GP2 is shown in tan, N-linked glycans are shown in orange, and the MLD (not included in the crystal structure) is modeled as a gray sphere. Two N-linked glycans found on GP2 were not mutated in our glycosylation mutants investigated in these studies and are shown around the base of GP2. *Left*, WT GP; *right*, 7Gm8G mutant lacking all GP1 N-linked glycans indicated by the absence of orange glycans modeled on GP1 and an increase in transparency of the MLD. (B) Vaccination regimen. (C) Protection conferred by 2×10^7 TU of EBOV GP/VSV pseudovirions ($n = 9$ /group) upon challenge of BALB/c mice with 1000 PFU of MA-EBOV. Significance was determined by Mantel-Cox Test, ** $p < 0.001$. (D) Sickness score of surviving mice at indicated days post infection. Data are presented as average $\pm$ SD.

UNCLASSIFIED




Figure 2: Survival of C57bl/6 females vaccinated with the indicated transducing units (TU) of VSV lacking its native glycoprotein and pseudotyped with EBOV GP (black lines), 7G (green lines), or 7Gm8G (blue lines) (n= 10/treatment). Transducing units (TU) were determined by Vero cell transduction of VSV/EBOV GP; pseudovirion equivalent of mutant viruses were normalized to WT levels by the quantity of VSV matrix in each stock. Vaccinated mice were challenged with 100 pfu MA-EBOV and monitored for 28 days. For comparison, the PBS control is shown for each dosage. Survival of PBS control mice was compared to the other vaccine treatments with significance determined by Mantel-Cox Test, * $p < 0.01$, ** $p < 0.001$.




Figure 3: Humoral responses in mice vaccinated with WT EBOV GP/VSV were more robust than that of mice vaccinated with deglycosylated pseudovirions. Sera were collected from vaccinated mice three weeks following boost. (A) Anti-EBOV GP Ig levels. Dashed line represents Ig levels observed in PBS-treated mice. (B) Correlation between the quantity of pseudovirus administered as a vaccine and Ig production. Trend line for each vaccine treatment is shown independently. (C) Correlation between group survival and anti-EBOV GP Ig in sera. Trend line is shown for pooled results from all three pseudovirion treatments. (D) Neutralizing activity present in vaccinated mice sera. Serum was serially diluted and incubated with EBOV GP/VSV for 30 minutes at 37°C prior to addition to Vero cells. Data are shown as transduction (GFP positive cells) presented as a percentage of PBS control. Significant differences in neutralization conferred by EBOV GP compared to either of the deglycosylated EBOV GP groups were determined by two-way ANOVA with Tukey post hoc analysis, * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$.

UNCLASSIFIED




Figure 4: VSV pseudovirions bearing deglycosylated EBOV GP do not provide protection against SUDV challenge. C57bl/6 IFNAR^{-/-} (n=10 mice) were primed and boosted with 2×10^7 TU of the indicated VSV pseudovirions followed by challenge with (A) 1000 pfu of WT SUDV or (B) 1000 pfu of WT EBOV. Percentage of weight loss is shown at the indicated time following infection.